- Home
- / Conatus Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Conatus Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.6
2020-05-29
Market Capitalization
$18.4 M
2020-05-29
Revenue
$3.8 M
FY, 2022
CreditSafe Score
?
Score changed on Jun 16, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 799.0K | 35.4M | 33.6M | 21.7M | 2.1M | 1.0M | 3.8M | |||
| General and administrative expense | 4.7M | 7.4M | 7.8M | 10.3M | 9.7M | 10.5M | 10.2M | 6.6M | 7.8M | 9.4M |
| Operating expense total | 11.6M | 22.3M | 24.1M | 30.6M | 52.9M | 51.9M | 33.7M | 12.8M | 14.4M | |
| EBIT | (29.8M) | (17.6M) | (18.3M) | (12.0M) | (18.9M) | (15.5M) | (10.6M) | |||
| EBIT margin, % | -3733.4% | -49.6% | -54.4% | -55.3% | -915.9% | -282.4% | ||||
| Investment income | 962.0K | 568.0K | (64.0K) | (10.0K) | (1.0K) | |||||
| Interest income | 22.1K | 57.6K | 67.9K | 138.4K | 892.2K | |||||
| Net Income | (15.6M) | (22.3M) | (24.1M) | (29.7M) | (17.4M) | (18.0M) | (11.4M) | (18.8M) | (15.0M) | (10.6M) |
| EPS | (3.5) |